Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 41 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

9 trials in Phase 3/4

Results Transparency

17%

4 of 23 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

N/A

9(26.5%)

Phase 2

8(23.5%)

Phase 1

8(23.5%)

Phase 4

5(14.7%)

Phase 3

4(11.8%)

34Total

N/A(9)

Phase 2(8)

Phase 1(8)

Phase 4(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (41)

Showing 20 of 41 trials

NCT01243437Phase 2Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans

Role: collaborator

NCT05385510Phase 1Completed

Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

Role: collaborator

NCT02811432Not ApplicableCompleted

Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa

Role: collaborator

NCT07265453Not ApplicableRecruiting

A Family-centred Approach Enhancing Cardiovascular Health in Ugandan Adolescents and Their Families

Role: lead

NCT04030520Not ApplicableCompleted

Improving Uptake and Adherence to HIV Prevention Services With Pre-exposure Prophylaxis (PrEP), HIV Self- Testing and Adherence Support for Very High Risk HIV-negative Young Women Aged 15-24 in Kampala, Uganda

Role: collaborator

NCT05048472Not ApplicableCompleted

East Africa Point of Care Viral Load Study

Role: lead

NCT03725618Phase 4Completed

Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old

Role: collaborator

NCT04066881Phase 2Completed

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

Role: lead

NCT05516602Not ApplicableCompleted

Improving HIV Prevention Among Adolescent Girls and Young Women (AGYW) in Uganda

Role: lead

NCT04549220Active Not Recruiting

Serosurveillance Study of Maternally Derived Anti-GBS Antibody

Role: collaborator

NCT04021121Phase 2Completed

Adjunctive Linezolid for the Treatment of Tuberculous Meningitis

Role: collaborator

NCT05546242Phase 3Active Not Recruiting

Improving HIV-1 Control in Africa with Long Acting Antiretrovirals

Role: lead

NCT05154747Phase 3Active Not Recruiting

Long-Acting Treatment in Adolescents (LATA)

Role: collaborator

NCT04059471Phase 4Completed

Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine

Role: collaborator

NCT04653948Unknown

Maternal, Neonatal and Infant Outcomes at Kawempe National Referral Hospital

Role: collaborator

NCT06133686Phase 3Not Yet Recruiting

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

Role: lead

NCT04732026Unknown

Serocorrelate of Protection Against GBS (PREPARE WP3)

Role: collaborator

NCT06093646Not ApplicableUnknown

Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda

Role: lead

NCT05999825Phase 2Unknown

Sm-p80 Schistosomiasis Challenge Study

Role: collaborator

NCT05909358Phase 1Not Yet Recruiting

Solidarity/Tokomeza Ebola Trial

Role: collaborator